NCT02573740 - Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Alzheimer's DiseaseMild Cognitive Impairment

Interventions

DRUG

ABT-957

OTHER

Placebo

Trial Locations (9)

Site Reference ID/Investigator# 149484, The Villages

Site Reference ID/Investigator# 143178, Orlando

Site Reference ID/Investigator# 143182, Cincinnati

Site Reference ID/Investigator# 149481, Dallas

Site Reference ID/Investigator# 143254, Orem

Site Reference ID/Investigator# 143179, Salt Lake City

Site Reference ID/Investigator# 143180, Cypress

Site Reference ID/Investigator# 143177, Spokane

Site Reference ID/Investigator# 143181, Marlton